Aim:We reviewed clinical characteristics, treatment outcomes of patients treated for Non-Small Cell Lung Cancer with brain metastases with whole brain radiotherapy plus conventional boost at a single institution were retrospectively evaluated.Material and Methods:Between 2000 and 2017, 296 patients who were diagnosed with Non-Small Cell Lung Cancer Patients with brain metastasis and referred to our clinic for radiotherapy were included in this retrospective study. Results:Median age was 60.8±12.1 years with a range of 21–85 years. The estimated median survival of all patients were 7.81±0.66 (95%CI:6.52-9.11) months, 1-, 2- and 3- year overall survival rates were 18.8%, 5.8%, and 2.9% respectively. The median survival and the 6- and 12-months survival rates of patients with solitary brain metastasis who received 45 Gy radiotherapy were 14.70±2.80 months (95%CI:9.20-20.20) and 65.4% and 42.6%, respectively; for those in patients with solitary brain metastasis who received surgery + 45 Gy radiotherapy, were 13.86±2.56 months (95%CI:8.08-18.02) and 66.2% and 27.2%, respectively. There was no significant difference between the two groups (p = 0.321). When assessed by age, median survival time of the patients ≤ 64 and ≥65 years 9.65±1.02 and 5.15±0.51 respectively. There were a statistically significant difference in median survival rates among the groups (p< 0.001).Conclusion:Our patients with solitary metastases and single metastases tolerated Whole Brain Radiotherapy plus conventional boost. Although overall survival rates were numerically better in high dose RT group, this difference could not gain statistical significance. Larger prospective studies are needed to improve our results.